Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Colorado State University | OTHER |
Not provided
Not provided
Not provided
Not provided
The aim of this study is to learn more about how physical activity and cardiorespiratory fitness are related to diabetes risk among breast cancer patients prescribed an endocrine therapy.
80 women between the ages of 18-80 years will be recruited for this study. The study design consists of two separate in-person visits to University of Colorado Anschutz Medical Campus or Colorado State University. The study consists of glucose testing, a body composition scan, exercise testing, and a two-week period of free living activity monitoring.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SERM | These patients are being treated with a SERM for at least one year prior to enrolling in the study. |
| |
| Aromatase Inhibitor | These patients are being treated with an aromatase inhibitor for at least one year prior to enrolling in the study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | No intervention is performed. Participants who have been treated with either a SERM or aromatase inhibitor are recruited and analyzed in separate groups, but the study design for all participants is identical. |
| Measure | Description | Time Frame |
|---|---|---|
| Insulin Resistance | Insulin resistance will be measured through oral glucose tolerance testing | Immediately after the consent form is signed |
| Body Composition | Body composition will be measured through DEXA scan | Immediately after the insulin resistance measurement |
| Maximal Exercise Capacity | Maximal exercise capacity measured through graded exercise test on stationary bicycle | Within 2-60 days of insulin resistance measurement |
| Daily Activity | Daily activity measured using activity monitor | 2-60 days following insulin resistance measurement |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Age < 18 or > 80
Type 1 diabetes
Type 2 diabetes
Prescribed anti-hyperglycemic medication, insulin, or sulfonylurea.
Pregnant, breastfeeding or planning to become pregnant in next 2 months
Have absolute contraindications to exercise testing which are:
Suspected cognitive impairment that would prevent understanding or comprehension of study procedures.
Biologically female.
Breast cancer survivors prescribed endocrine therapy for at least one year
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rebecca Scalzo, PhD | University of Colorado, Denver | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| D009043 | Motor Activity |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood Samples
| D017437 |
| Skin and Connective Tissue Diseases |
| D001519 | Behavior |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |